Celltrion boasts worldwide tech lead in biosimilars

South Korea has more biosimilar firepower than just consumer electronics convert Samsung. Celltrion, under the leadership of Seo Jung-jin, is a biosimilars "front-runner," says the CEO. Celltrion has "about four to five years" of a technology lead over rivals, he says. "There will be no serious competitor by 2015, in which period the industry's capacity will be short of demand," Seo says. Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.